CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000167 | inverse_isa | C1254351 | 17-Ketosteroids | Pharmacologic Substance | Steroids that contain a ketone group at position 17. | Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances. |
C0000167 | measures | C1254616 | 17-Ketosteroids | Urine 17-Ketosteroids Test | Steroids that contain a ketone group at position 17. | null |
C0000167 | measures | C1255082 | 17-Ketosteroids | 24 Hour Urine 17-Ketosteroids Test | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0014942 | 17-Ketosteroids | estrone | Steroids that contain a ketone group at position 17. | An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. |
C0000167 | isa | C0046200 | 17-Ketosteroids | 2-hydroxyestrone | Steroids that contain a ketone group at position 17. | A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 2 by cytochrome P450 (CYP) enzymes, including CYP1A1 and 1A2, with potential anticarcinogenic activity. The mechanism of action for the antitumor activity of 2-hydroxyestrone is not known but this metabolic product has minimal estrogenic activity compared to the parent compound and other estrone metabolites. Additionally, O-methylation of this compound produces 2-methoxyestradiol (2-MeOE2), which is a potent inhibitor of both cell proliferation and angiogenesis. |
C0000167 | isa | C0048306 | 17-Ketosteroids | formestane | Steroids that contain a ketone group at position 17. | A synthetic steroidal substance with antineoplastic activity. Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04) |
C0000167 | isa | C0059668 | 17-Ketosteroids | estrone sulfate | Steroids that contain a ketone group at position 17. | An aqueous substance that is the sulfate salt form of estrone. (NCI) |
C0000167 | isa | C0071108 | 17-Ketosteroids | estropipate | Steroids that contain a ketone group at position 17. | A natural estrogenic substance composed of estrone sulfate and piperazine. Estropipate diffuses through the cell membrane and binds to and subsequently activates the nuclear estrogen receptor found in the reproductive tract, breast, pituitary, hypothalamus, liver, and bone. The activated complex binds to the estrogen response element on the DNA and activates the transcription of genes involved in the functioning of the female reproductive system and secondary sex characteristics. |
C0000167 | isa | C0071553 | 17-Ketosteroids | polyestradiol | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0071554 | 17-Ketosteroids | polyestradiol phosphate | Steroids that contain a ketone group at position 17. | A synthetic long-acting polymer derivative of the female sex hormone estradiol. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Administration of polyestradiol phosphate leads to the marked decrease of testosterone levels and may exhibit a bone mass-preserving effect in patients with prostatic cancer. (NCI04) |
C0000167 | isa | C0077144 | 17-Ketosteroids | trilostane | Steroids that contain a ketone group at position 17. | A synthetic derivative of androstane with adrenocortical suppressive properties. Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. (NCI04) |
C0000167 | isa | C0090532 | 17-Ketosteroids | 16 alpha-hydroxyestrone | Steroids that contain a ketone group at position 17. | A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 16 by cytochrome P450 (CYP) family enzymes, including CYP3A4 and 3A5, with potential carcinogenic activity. With increased estrogenic activity compared to the parent compound, 16alpha-hydroxyestrone (16alpha-OHE1) increases the expression of ER-responsive genes, which leads to increased proliferation of susceptible tumor cells. The ratio between the two estrogen metabolites, 2-hydroxyestrone (2-OHE1), a weak estrogen and metabolite from the 2-hydroxylation pathway, and 16alpha-OHE1, a metabolite from the 16-hydroxylation pathway, may be used to assess the risk of certain cancers; a higher ratio of 2-OHE1:16alpha-OHE1 correlates with decreased cancer risk. |
C0000167 | isa | C0304783 | 17-Ketosteroids | sodium estrone sulfate | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0369197 | 17-Ketosteroids | Estrone, unconjugated | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0522262 | 17-Ketosteroids | 11-deoxy-17-ketosteroid | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0522267 | 17-Ketosteroids | 11-oxy-17-ketosteroid | Steroids that contain a ketone group at position 17. | null |
C0000167 | isa | C0851344 | 17-Ketosteroids | exemestane | Steroids that contain a ketone group at position 17. | An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation. |
C0000167 | isa | C0935916 | 17-Ketosteroids | fulvestrant | Steroids that contain a ketone group at position 17. | An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer. |
C0000167 | has_component | C0202112 | 17-Ketosteroids | 17-Ketosteroids measurement, fractionation, urine | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_measured_component | C0202112 | 17-Ketosteroids | 17-Ketosteroids measurement, fractionation, urine | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0236402 | 17-Ketosteroids | 17-Ketogenic Steroid Measurement | Steroids that contain a ketone group at position 17. | The determination of the amount of total 17-ketogenic steroids present in a sample. |
C0000167 | has_component | C0236402 | 17-Ketosteroids | 17-Ketogenic Steroid Measurement | Steroids that contain a ketone group at position 17. | The determination of the amount of total 17-ketogenic steroids present in a sample. |
C0000167 | has_measured_component | C0236402 | 17-Ketosteroids | 17-Ketogenic Steroid Measurement | Steroids that contain a ketone group at position 17. | The determination of the amount of total 17-ketogenic steroids present in a sample. |
C0000167 | has_component | C0373659 | 17-Ketosteroids | Ketogenic steroids, fractionation | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0373659 | 17-Ketosteroids | Ketogenic steroids, fractionation | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0373661 | 17-Ketosteroids | Ketosteroids, 17- (17-KS); fractionation | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0523730 | 17-Ketosteroids | 17-Ketosteroids measurement, total | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_measured_component | C0523730 | 17-Ketosteroids | 17-Ketosteroids measurement, total | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0523732 | 17-Ketosteroids | Ketogenic steroids challenge tests | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0580402 | 17-Ketosteroids | Urine 17 ketogenic steroid measurement | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0702125 | 17-Ketosteroids | 17-Ketogenic steroids measurement, 24H urine | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1278012 | 17-Ketosteroids | Plasma 17-oxosteroid measurement | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_measured_component | C1278012 | 17-Ketosteroids | Plasma 17-oxosteroid measurement | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1278015 | 17-Ketosteroids | Serum 17-oxosteroid measurement | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_measured_component | C1278015 | 17-Ketosteroids | Serum 17-oxosteroid measurement | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C5874624 | 17-Ketosteroids | 17-ketosteroids and 17-ketogenic steroids panel in 24 hour urine | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0484621 | 17-Ketosteroids | 17-Ketosteroids:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0550164 | 17-Ketosteroids | 17-Ketosteroids.total neutral:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0797748 | 17-Ketosteroids | 17-Ketosteroids:SRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0803834 | 17-Ketosteroids | 17-Ketosteroids:MCnc:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0941484 | 17-Ketosteroids | 17-Ketosteroids:SCnc:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C0944819 | 17-Ketosteroids | 17-Ketosteroids.total neutral:MRat:12H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1315816 | 17-Ketosteroids | 17-Ketosteroids/Creatinine:MRto:Pt:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1316685 | 17-Ketosteroids | 17-Ketosteroids:SCnc:Pt:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1316686 | 17-Ketosteroids | 17-Ketosteroids/Creatinine:SRto:Pt:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1631262 | 17-Ketosteroids | 17-Ketosteroids & 17-Ketogenic steroids panel:-:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1715537 | 17-Ketosteroids | 17-Ketosteroids/Creatinine:MRto:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1953319 | 17-Ketosteroids | 17-Ketosteroids:MCnc:Pt:Ser:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1977931 | 17-Ketosteroids | 17-Ketosteroids^post dose dexamethasone:MCnc:Pt:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1977932 | 17-Ketosteroids | 17-Ketosteroids^2D post dose dexamethasone:MCnc:Pt:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978076 | 17-Ketosteroids | 17-Ketosteroids^post high dose dexamethasone:MCnc:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978077 | 17-Ketosteroids | 17-Ketosteroids^2D post high dose dexamethasone:MCnc:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978078 | 17-Ketosteroids | 17-Ketosteroids^post dose dexamethasone:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978079 | 17-Ketosteroids | 17-Ketosteroids^2D post dose dexamethasone:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978103 | 17-Ketosteroids | 17-Ketosteroids^post high dose dexamethasone:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000167 | has_component | C1978104 | 17-Ketosteroids | 17-Ketosteroids^2D post high dose dexamethasone:MRat:24H:Urine:Qn | Steroids that contain a ketone group at position 17. | null |
C0000172 | mapped_to | C0045029 | 18-Hydroxycorticosterone | 18,19-dihydroxycorticosterone | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | mapped_to | C0045037 | 18-Hydroxycorticosterone | 18-hydroxy-11-dehydrotetrahydrocorticosterone | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | mapped_to | C0045038 | 18-Hydroxycorticosterone | 18-hydroxy-19-norcorticosterone | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | mapped_to | C0296039 | 18-Hydroxycorticosterone | 18-hydroxytetrahydrocorticosterone | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | associated_with | C0523734 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone measurement | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | The determination of the amount of 18-hydroxycorticosterone present in a sample. |
C0000172 | measures | C0363808 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C0484623 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MRat:24H:Urine:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C1639933 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MCnc:Pt:Urine:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C1977937 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C2735541 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^pre dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C2735542 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | measures | C2735543 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | inverse_isa | C0443588 | 18-Hydroxycorticosterone | Steroid metabolism disorder marker | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | inverse_isa | C0486267 | 18-Hydroxycorticosterone | 18-hydroxycorticosteroid | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C0523734 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone measurement | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | The determination of the amount of 18-hydroxycorticosterone present in a sample. |
C0000172 | has_measured_component | C0523734 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone measurement | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | The determination of the amount of 18-hydroxycorticosterone present in a sample. |
C0000172 | disposition_of | C4521954 | 18-Hydroxycorticosterone | Adrenal cortex hormone (disposition) | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C0363808 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C0484623 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MRat:24H:Urine:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C1639933 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:MCnc:Pt:Urine:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C1977937 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C2735541 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^pre dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C2735542 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000172 | has_component | C2735543 | 18-Hydroxycorticosterone | 18-Hydroxycorticosterone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn | 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione. | null |
C0000173 | mapped_to | C0044909 | 18-Hydroxydesoxycorticosterone | 16 alpha,18-dihydroxydeoxycorticosterone | An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position. | null |
C0000173 | mapped_to | C0045030 | 18-Hydroxydesoxycorticosterone | 18,19-dihydroxydeoxycorticosterone | An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position. | null |
C0000173 | mapped_to | C0045031 | 18-Hydroxydesoxycorticosterone | 18,20-cyclo-20,21-dihydroxy-4-pregnen-3-one | An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position. | null |
C0000173 | mapped_to | C0601554 | 18-Hydroxydesoxycorticosterone | 18-hydroxytetrahydrodeoxycorticosterone | An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position. | null |
C0000173 | mapped_to | C0609759 | 18-Hydroxydesoxycorticosterone | 3 alpha,18,21-trihydroxy-5 beta-pregnan-20-one 18-20-hemiacetal | An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position. | null |
C0000176 | mapped_to | C0045064 | 19-Iodocholesterol | 19-iodocholesterol 3-acetate | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0045065 | 19-Iodocholesterol | 19-iodocholesteryl oleate | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0049631 | 19-Iodocholesterol | 6-iodomethylcholesterol | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0609433 | 19-Iodocholesterol | I-norcholesterol | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0610157 | 19-Iodocholesterol | 3 beta-methoxy-6-beta-iodomethyl-19-norcholest-5(10)ene | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0610159 | 19-Iodocholesterol | 3 beta-fluoro-6 beta-iodomethyl-19-norcholest-5(10)ene | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0612676 | 19-Iodocholesterol | 19-iodocholesterol 3-methyl ether | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000176 | mapped_to | C0612677 | 19-Iodocholesterol | 19-iodocholesterol 3-ethyl ether | 19-Iodocholest-5-en-3 beta-ol. A cholesterol derivative usually substituted with radioactive iodine in the 19 position. The compound is an adrenal cortex scanning agent used in the assessment of patients suspected of having Cushing's syndrome, hyperaldosteronism, pheochromocytoma and adrenal remnants following total adrenalectomy. | null |
C0000184 | mapped_to | C0045103 | 2',3'-Cyclic-Nucleotide Phosphodiesterases | 2',3'-Cyclic-nucleotide 2'-phosphodiesterase | Nucleoside-2',3'-cyclic phosphate nucleotidohydrolase. Enzymes that catalyze the hydrolysis of the 2'- or 3'- phosphate bonds of 2',3'-cyclic nucleotides. Also hydrolyzes nucleoside monophosphates. Includes EC 3.1.4.16 and EC 3.1.4.37. EC 3.1.4.-. | null |
C0000184 | mapped_to | C0538287 | 2',3'-Cyclic-Nucleotide Phosphodiesterases | gRICH68 protein, Carassius auratus | Nucleoside-2',3'-cyclic phosphate nucleotidohydrolase. Enzymes that catalyze the hydrolysis of the 2'- or 3'- phosphate bonds of 2',3'-cyclic nucleotides. Also hydrolyzes nucleoside monophosphates. Includes EC 3.1.4.16 and EC 3.1.4.37. EC 3.1.4.-. | null |
C0000184 | mapped_to | C0538288 | 2',3'-Cyclic-Nucleotide Phosphodiesterases | gRICH70 protein, Carassius auratus | Nucleoside-2',3'-cyclic phosphate nucleotidohydrolase. Enzymes that catalyze the hydrolysis of the 2'- or 3'- phosphate bonds of 2',3'-cyclic nucleotides. Also hydrolyzes nucleoside monophosphates. Includes EC 3.1.4.16 and EC 3.1.4.37. EC 3.1.4.-. | null |
C0000184 | mapped_to | C4508243 | 2',3'-Cyclic-Nucleotide Phosphodiesterases | CpdB protein, E coli | Nucleoside-2',3'-cyclic phosphate nucleotidohydrolase. Enzymes that catalyze the hydrolysis of the 2'- or 3'- phosphate bonds of 2',3'-cyclic nucleotides. Also hydrolyzes nucleoside monophosphates. Includes EC 3.1.4.16 and EC 3.1.4.37. EC 3.1.4.-. | null |
C0000189 | mapped_to | C0758633 | 2-5A Synthetase | OASL protein, human | An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions. | null |
C0000189 | mapped_to | C0760017 | 2-5A Synthetase | p56 oligoadenylate synthetase | An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions. | null |
C0000189 | mapped_to | C0760019 | 2-5A Synthetase | p30 oligoadenylate synthetase | An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions. | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.